Navigation Links
Cell Therapeutics to Present at Upcoming Investor Conferences

SEATTLE, May 15, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that management will present at the following upcoming investor conferences. 

UBS Global Healthcare Conference
Tuesday, May 21, 2013 at 2:30 p.m. Eastern Time in New York, NY

Jefferies 2013 Global Healthcare Conference
Tuesday, June 4, 2013 at 3:00 p.m. Eastern Time in New York, NY

The presentations will also be webcast live and available for replay after the presentation.  The webcast can be accessed at

About Cell Therapeutics, Inc.

Cell Therapeutics (NASDAQ and MTA: CTIC) is a biopharmaceutical company committed to the development and commercialization of an integrated portfolio of oncology products aimed at making cancer more treatable. CTI is headquartered in Seattle, WA. For additional information and to sign up for email alerts and get RSS feeds, please visit the company's website at

Media and Investor Contacts:

Cell Therapeutics, Inc.

Monique Greer
T: +1 206.272.4343

Ed Bell
T: +1 206.272.4345

In Europe

CTI Life Sciences Limited, Milan Branch

Laura Villa
Elena Bellacicca

T: +39 02 89659700

SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
2. ASGCT Annual Meeting to Highlight Latest Advances in Genetic and Cellular Therapeutics
3. Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2013
4. Henri A. Termeer Joins Moderna Therapeutics Board Of Directors
5. Oxford BioTherapeutics and Boehringer Ingelheim Enter Collaboration to Discover Novel Antibody Targets in Cancer
6. Orexigen Therapeutics Commends the Campaign to End Obesitys Report on Long-term Returns of Obesity Prevention Policies
7. Cell Therapeutics to Report First Quarter Financial Results after Market on May 2, 2013
8. United Therapeutics Corporation To Announce First Quarter 2013 Financial Results Before Market Open On Thursday, April 25, 2013
9. Nanotherapeutics Awarded Defense Department Contract for Advanced Development and Manufacturing of Medical Countermeasures
10. Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics (UK) Ltd.
11. Resverlogix desincorpora RVX Therapeutics Inc. para sus accionistas
Post Your Comments:
(Date:6/23/2016)... A person commits a crime, and the detective ... the criminal down. An outbreak of foodborne illness ... (FDA) uses DNA evidence to track down the bacteria that ... It,s not. The FDA has increasingly used a complex, cutting-edge ... illnesses. Put as simply as possible, whole genome sequencing is ...
(Date:6/23/2016)... FRANCISCO , June 23, 2016   EpiBiome ... has secured $1 million in debt financing from Silicon ... ramp up automation and to advance its drug development ... its new facility. "SVB has been an ... beyond the services a traditional bank would provide," said ...
(Date:6/23/2016)... 23, 2016  Blueprint Bio, a company dedicated to ... medical community, has closed its Series A funding round, ... "We have received a commitment from Forentis ... need to meet our current goals," stated Matthew ... runway to complete validation on the current projects in ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, a division of ... and optimized exclusively for Okuma CNC machining centers at The International Manufacturing Technology ... among several companies with expertise in toolholding, cutting tools, machining dynamics and distribution, ...
Breaking Biology Technology:
(Date:5/24/2016)... , May 24, 2016 Ampronix facilitates superior patient care by providing ...  3D medical LCD display is the latest premium product recently added to the range ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/19/2016)... The new GEZE SecuLogic access ... "all-in-one" system solution for all door components. It can ... door interface with integration authorization management system, and thus ... minimal dimensions of the access control and the optimum ... offer considerable freedom of design with regard to the ...
Breaking Biology News(10 mins):